4.8 Review

Perspectives and opportunities for nanomedicine in the management of atherosclerosis

Journal

NATURE REVIEWS DRUG DISCOVERY
Volume 10, Issue 11, Pages 835-852

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nrd3578

Keywords

-

Funding

  1. International Atherosclerosis Society
  2. National Heart, Lung, and Blood Institute (NHLBI)
  3. US National Institutes of Health (NIH) [HHSN268201000045C]
  4. NIH [R01 EB009638, R01 CA155432]

Ask authors/readers for more resources

The use of nanotechnology for medical purposes - nanomedicine - has grown exponentially over the past few decades. This is exemplified by the US Food and Drug Administration's approval of several nanotherapies for various conditions, as well as the funding of nanomedical programmes worldwide. Although originally the domain of anticancer therapy, recent advances have illustrated the considerable potential of nanomedicine in the diagnosis and treatment of atherosclerosis. This Review elaborates on nanoparticle-targeting concepts in atherosclerotic disease, provides an overview of the use of nanomedicine in atherosclerosis, and discusses potential future applications and clinical benefits.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available